115 results on '"Ganguly, Shuvadeep"'
Search Results
102. Neoadjuvant cemiplimab for stages II to IV cutaneous squamous cell carcinoma.
- Author
-
Chib, Sushant, Ganguly, Shuvadeep, and Gogia, Ajay
- Published
- 2022
- Full Text
- View/download PDF
103. Pembrolizumab in Early Triple-Negative Breast Cancer.
- Author
-
Ganguly, Shuvadeep and Gogia, Ajay
- Published
- 2022
- Full Text
- View/download PDF
104. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.
- Author
-
GANGULY, SHUVADEEP and GOGIA, AJAY
- Published
- 2022
- Full Text
- View/download PDF
105. Sacituzumab Govitecan in Metastatic Breast Cancer.
- Author
-
Ganguly, Shuvadeep and Gogia, Ajay
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *IMMUNOGLOBULINS , *CAMPTOTHECIN , *BREAST tumors - Published
- 2021
- Full Text
- View/download PDF
106. Isolated native Tricuspid Valve Endocarditis Presenting as PUO in a Young Adult Male Without Any Risk Factors.
- Author
-
Ranjan, Piyush, Kumar, Vivek, Ganguly, Shuvadeep, Vyas, Surabhi, Yadav, Rakesh, and Sood, Rita
- Subjects
TRICUSPID valve diseases ,FEVER ,WEIGHT loss ,INFECTION - Abstract
A 28-year-old male presented to our hospital with high-grade fever and weight loss for 4 months. Clinical examination was non-contributory and there was no history of any high-risk behavior or prolonged skin or dental infections. Native tricuspid-valve endocarditis may rarely present in these settings and high index of suspicion is essential for early diagnosis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
107. PD-1 Blockade in Mismatch Repair-Deficient Rectal Cancer.
- Author
-
Copur, Mehmet S., Soe Min Tun, Duckert, Randall, Ganguly, Shuvadeep, Gogia, Ajay, and Tun, Soe Min
- Subjects
- *
RECTAL cancer , *HEREDITARY nonpolyposis colorectal cancer , *PROGRAMMED cell death 1 receptors , *EPIDERMAL growth factor receptors , *CIRCULATING tumor DNA - Published
- 2022
- Full Text
- View/download PDF
108. Comment on: Cost-effectiveness of treating childhood acute myeloid leukemia at a tertiary care center in North India.
- Author
-
Sra MS, Bakhshi S, and Ganguly S
- Published
- 2024
- Full Text
- View/download PDF
109. Ewing sarcoma among children 5 years of age or younger: Is it a different disease?
- Author
-
Nagpal C, Ganguly S, Sasi A, Kumar V, Biswas B, Pushpam D, Kumar A, Agarwala S, Jain V, Dhua A, Yadav DK, Khan SA, Barwad A, Mirdha AR, Biswas A, Thulkar S, and Bakhshi S
- Abstract
Introduction: Children ≤5 years of age with Ewing's sarcoma (ES) possibly have a distinct disease biology, data on which are scarce. We evaluated clinical features, outcomes, and prognostic factors of ES among children with age ≤5 years., Methods: Children with ES registered between 2003 and 2019 were included. Baseline clinical and treatment details were retrieved from medical records. Prognostic factors were identified using multivariable Cox regression. Clinical features and outcomes of children ≤5 years were compared with those greater than 5 years by chi-square and log-rank tests. Propensity score-matched (PSM) analysis was done to evaluate the impact of age on survival in the metastatic and localized subgroups., Results: Out of the 859 patients, 86 (10%) were ≤5 years of age (median age 4 years, 60 males [69.8%]). The most common location was the extremities (37.2%), followed by thorax (27.9%) and head and neck (H&N) (22.1%); baseline metastases were seen in 25 patients (29.8%). The median event-free-survival (EFS) and overall survival (OS) were 25.6 and 68.7 months, respectively. Metastatic disease predicted inferior OS (hazard ratio [HR] = 2.54, p = .018) and EFS (HR = 2.47, p = .007], symptom duration ≤3 months predicted an inferior OS (HR = 2.17, p = .048). Compared to age greater than 5 years, younger children had more H&N and less pelvic primaries (p < .001) and lesser baseline metastases (p = .037). PSM analysis did not reveal any significant impact of age on OS in the metastatic (HR = 1.59, p = .29) or localized cohort (HR = 1.77, p = .09)., Conclusions: Children with ES ≤5 years of age have a distinct favorable clinical presentation. However, age is not an independent prognostic factor for survival outcomes when adjusted for confounders., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
110. Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor-Positive Early Breast Cancer: An Indian Perspective.
- Author
-
Sra MS, Sasi A, Batra A, Bakhshi S, and Ganguly S
- Subjects
- Humans, Female, India, Chemotherapy, Adjuvant economics, Chemotherapy, Adjuvant methods, Quality-Adjusted Life Years, Antineoplastic Combined Chemotherapy Protocols economics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Markov Chains, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Aminopyridines economics, Aminopyridines administration & dosage, Aminopyridines therapeutic use, Benzimidazoles economics, Benzimidazoles administration & dosage, Benzimidazoles therapeutic use, Purines economics, Purines administration & dosage, Breast Neoplasms drug therapy, Breast Neoplasms economics, Cost-Benefit Analysis
- Abstract
Purpose: Incorporating adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitors abemaciclib and ribociclib along with endocrine therapy has been shown to improve invasive disease-free survival (iDFS) for hormone receptor-positive (HR+) human epidermal receptor 2-negative (HER2-) early breast cancer (EBC). This study assesses the cost-effectiveness of this strategy, along with adjuvant aromatase inhibitors from an Indian perspective., Methods: A Markov chain model evaluated the cost-effectiveness of abemaciclib and ribociclib with letrozole compared with letrozole alone for HR+/HER2- EBC from a payer perspective in India. Key measures included lifetime quality-adjusted life-years (QALY), life-years (LY), and total costs. This study explores two scenarios for effectiveness: a best-case (BC) scenario, where the benefit of CDK4/6 inhibitors in improving iDFS lasts a lifetime, and a worst-case (WC) scenario, where benefits disappear after 5 years. Probabilistic sensitivity analyses (PSA) were used to account for simulation uncertainty., Results: In the BC scenario, abemaciclib added 2.17 QALY and 4.96 LY, incurring ₹2,317,957.7 ($27,756.65 in US dollars [USD]) in additional costs. However, the incremental cost-effectiveness ratio (ICER) for abemaciclib exceeded India's willingness-to-pay threshold in the BC and WC scenarios. In the BC scenario, ribociclib added 0.98 QALY and 2.58 LY with added costs of ₹1,711,504.32 ($20,494.6 USD). The ICER for ribociclib also surpassed India's threshold in both scenarios. PSA showed that neither drug was cost-effective at the current market prices in either BC/WC scenario. The cost of abemaciclib and ribociclib needs to be reduced by at least 78.61% and 87.19%, respectively, to be cost-effective in the BC scenario., Conclusion: The combination of adjuvant abemaciclib or ribociclib with letrozole is not cost-effective for HR+/HER2- EBC in India in either the BC or WC scenario.
- Published
- 2024
- Full Text
- View/download PDF
111. Knowledge and attitude on childhood cancer survivorship among healthcare trainees: a multicentre study from India.
- Author
-
Grewal A, Bansal B, Mittal C, Gupta H, Sasi A, Ganesan P, Dabas A, Sahi P, Ramamoorthy L, Lalthanthuami HT, Ramamoorthy J, Sindhu A, Arora S, Bhukya A, Hepzibah M, Devi K, Krishnamurthy K, Rai SK, Mehta N, Antil K, Bakhshi S, and Ganguly S
- Subjects
- Adult, Female, Humans, Young Adult, Cross-Sectional Studies, Delivery of Health Care, Survivorship, Cancer Survivors psychology, Neoplasms psychology
- Abstract
Background: The proportion of childhood cancer survivors (CCS) in low/middle-income countries (LMICs) is rising. CCS often develop several physical and psycho-social long-term adverse effects, with unique healthcare needs. Primary healthcare providers (primary care physicians (PCPs)), especially in LMICs, are often not equipped to handle survivorship care. This study aimed to assess knowledge, and attitude among trainee healthcare providers concerning major issues of paediatric survivorship care., Methods: A multi-centre, cross-sectional, questionnaire-based study was conducted among nursing and medical undergraduate students, and postgraduate medical residents across three tertiary-care teaching hospitals in India-All India Institute of Medical Sciences, New Delhi; Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry; and Maulana Azad Medical College, New Delhi. A questionnaire with total of 24 questions (14 knowledge-based and 10 attitude-based) was finalised after validation by expert review and piloting. The major domains covered in the questionnaire included knowledge and attitude regarding long-term adverse effects and psychosocial, employment-related issues faced by the survivors. It was administered to the study participants electronically. The knowledge-based questions had true/false responses (scored as 0 or 1 if incorrect or correct, respectively). Attitude-based questions were scored as 5-point Likert scale., Results: Total 898 responses were collected (median age: 21 years, 64% (576/898) female). Among the respondents, 44% were undergraduate medical students, 42% were nursing students and 14% were postgraduate medical residents. The mean (SD) of knowledge score was 8.72 (2.04) (out of 14). On multivariable analysis, only discipline of training predicted knowledge scores regarding survivorship care. Postgraduate medical residents (9.08) as well as undergraduate medical students (8.85), had significantly higher mean knowledge scores than nursing students (8.47) (p=0.004).Two questions were answered incorrectly by the majority; children and siblings of CCS need additional genetic screening (79% incorrectly answered true), and CCS face intimacy issues in relation to normal sexual functioning (59% incorrectly answered false).Nearly half (48%) of respondents believed that their knowledge of cancer survivorship issues was inadequate. Majority of respondents (84%) suggested that oncologists should handle long-term survivorship care rather than PCPs., Conclusion: Trainee healthcare providers in India reported inadequate knowledge regarding survivorship care. Improving awareness by incorporating survivorship in teaching curriculum is imperative to equip future PCPs to provide survivorship care across the country., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
112. Olanzapine cost-effectiveness in vomiting and nausea from highly emetogenic chemotherapy in children and adolescents.
- Author
-
Sra MS, Ganguly S, Naik RD, Sasi A, Sharma P, Giri RK, Abdul Rasheed A, and Bakhshi S
- Subjects
- Adolescent, Child, Humans, Cost-Benefit Analysis, Dexamethasone therapeutic use, Nausea chemically induced, Nausea drug therapy, Nausea prevention & control, Olanzapine therapeutic use, Vomiting chemically induced, Vomiting drug therapy, Vomiting prevention & control, Randomized Controlled Trials as Topic, Antiemetics therapeutic use, Antineoplastic Agents adverse effects
- Abstract
Objectives: To assess the cost-effectiveness of addition of olanzapine to a prophylactic antiemetic regimen containing aprepitant, dexamethasone and ondansetron among children receiving highly emetogenic chemotherapy (HEC) in India, Bangladesh, Indonesia, the UK and the USA., Methods: Health states were estimated using individual patient-level outcome data from a randomised trial. The incremental cost-utility ratio (ICUR), incremental cost-effectiveness ratio and net monetary benefit (NMB) were calculated from the patient perspective for India, Bangladesh, Indonesia, the UK and the USA. One-way sensitivity analysis was done by varying the cost of olanzapine, cost of hospitalisation and utility values by ±25%., Results: The olanzapine arm had an increment of 0.0018 quality-adjusted life-years (QALY) over the control arm. The mean total expenditure in the olanzapine arm was greater by US$0.51, US$0.43, US$6.73, US$11.05 and US$12.35 in India, Bangladesh, Indonesia, the UK and the USA, respectively. The ICUR($/QALY) was US$282.60 in India, US$241.42 in Bangladesh, US$3755.93 in Indonesia, US$6161.83 in the UK and US$6887.41 in the USA. The NMB was US$9.86, US$10.12, US$14.08, US$44.74 and US$98.79 for India, Bangladesh, Indonesia, the UK and the USA, respectively. The ICUR estimates of the base case and sensitivity analysis were below the willingness-to-pay threshold in all scenarios., Conclusion: The addition of olanzapine as a fourth agent for antiemetic prophylaxis is cost-effective despite an increase in overall expenditure. Olanzapine should be uniformly considered for children receiving HEC., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
113. PD-1 Blockade in Mismatch Repair-Deficient Rectal Cancer.
- Author
-
Ganguly S and Gogia A
- Subjects
- B7-H1 Antigen, Humans, Programmed Cell Death 1 Receptor, DNA Mismatch Repair, Rectal Neoplasms genetics
- Published
- 2022
- Full Text
- View/download PDF
114. Development and validation of a prognostic score at baseline diagnosis for Ewing sarcoma family of tumors: a retrospective single institution analysis of 860 patients.
- Author
-
Sasi A, Ganguly S, Biswas B, Pushpam D, Kumar A, Agarwala S, Khan SA, Kumar VS, Deo S, Sharma DN, Biswas A, Mridha A, Barwad A, Thulkar S, and Bakhshi S
- Abstract
Introduction: Prognostic scores in Ewing sarcoma including baseline clinical and laboratory characteristics are necessary for pre-treatment risk stratification. In this study, we formulated and validated a prognostic model for baseline risk categorization in Ewing sarcoma., Materials and Methods: A retrospective single-institutional study was conducted on Ewing sarcoma patients treated uniformly between January 2003 and December 2018. Baseline clinical/pathological characteristics and survival outcomes were noted from medical records. The cohort was randomised into a derivation and validation cohort. A prognostic score was formulated by including independent prognostic factors from the derivation cohort by multivariable analysis. The prognostic model was validated in the validation cohort along with estimation of its predictive ability., Results: A total of 860 patients were included with 40.3% having baseline metastases. Tumor diameter >5 cm (HR 2.04; P<0.001; score 2), baseline metastases (HR 2.33; P<0.001, score 2), and total leucocyte count >11000/mm
3 (HR 1.44; P=0.015; score 1) were independent predictors of overall survival in derivation cohort and included for prognostic score calculation. Patients were categorized into low (score 0), intermediate (score 1-3) and high-risk (score 4-5) groups. Harrell's c-indexes of the model were 0.625, 0.622 and 0.624 in the derivation, validation and whole cohort respectively. The timed AUC of ROC of the prognostic score-group for 5-year survival was 0.72, 0.71 and 0.73 in the derivation, validation and whole cohort respectively., Conclusions: We have formulated and validated a prognostic score for Ewing sarcoma incorporating baseline clinical and laboratory parameters, with fair predictive ability for risk stratification and facilitating risk-adapted personalized therapy., Competing Interests: None., (AJTR Copyright © 2022.)- Published
- 2022
115. Mitochondrial complex II and V activity is enhanced in pediatric acute myeloid leukemia.
- Author
-
Chaudhary S, Ganguly S, Singh A, Palanichamy JK, Chopra A, Bakhshi R, and Bakhshi S
- Abstract
Background: Mitochondrial bioenergetic alterations are commonly observed metabolic adaptation in malignancies including acute myeloid leukemia (AML). Mitochondrial DNA alterations are well known in pediatric AML with possible prognostic significance; however, mitochondrial complex activity and its impact on disease outcome have not been previously explored. The aim of this study was to evaluate the mitochondrial complex II and complex V activity and its prognostic significance in pediatric AML patients., Methods: Consecutive 82 de novo pediatric (≤18 years) patients with AML were included in the study along with age and sex matched controls. Bone marrow mononuclear cells were isolated from baseline bone marrow samples from all patients and controls. DNA, RNA and proteins were extracted and relative expression of mitochondrial biogenesis genes TFAM , POLG , POLRMT were estimated along with mitochondrial DNA copy number. The mitochondrial complex II and V enzymes were immunocaptured and their activity was measured by substrate specific absorbance change by kinetic ELISA. The mitochondrial complex II and V activity was compared with controls and their association with clinico-pathological features and survival outcome were analysed. Complex activity was also correlated with relative expression of biogenesis genes., Results: The activity of mitochondrial complex II and V were found to be significantly enhanced (P = 0.010 and P = 0.0013 respectively) in pediatric AML patients compared to controls. The activity of mitochondrial complex II and V showed significant positive correlation with relative gene expression of mitochondrial biogenesis genes TFAM (P = 0.001 and P = 0.016 respectively) and POLG (P = 0.005 and P = 0.006 respectively). Neither of the two complex activities showed any significant association with baseline disease demographics or any clinico-pathological feature. Furthermore, the complex II and V activity did not show any impact on event free survival (P = 0.25 and P = 0.24 respectively) and overall survival (P = 0.14 and P = 0.17 respectively) in our cohort., Conclusion: The activity of both mitochondrial complex II and V are significantly elevated in bone marrow mononuclear cells of children with AML compared to controls. The enhanced activity may be related to upregulation of mitochondrial biogenesis genes TFAM and POLG . The enhanced activity of either of the complexes did not impact disease biology or survival outcomes in pediatric AML., Competing Interests: None., (AJBR Copyright © 2021.)
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.